The Coburn Lab studies microbe-host interactions at mucosal surfaces in the lung, gut and genital tract that modulate local and systemic immune responses. Our focus is on human disease and response to therapy in cancer, solid organ transplantation and critical illness (i.e. in the ICU). Our primary aim is to develop novel forms of immunomodulation which act through therapeutic augmentation of the composition and function of mucosal microbiota, including the use of diet, therapeutic bacteria or microbial consortia and antimicrobials. We combine human observational studies, mechanistic preclinical models and interventional human trials to address these goals.